{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-051361","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.102679+00:00","generated_at":"2026-05-19T22:41:45.117858+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial","bullets":["Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.","Trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell NHL.","Open-label, dose escalation/expansion Phase I/II study to determine Recommended Phase II Dose in adults ≥18.","CEO Cheng Liu states partnership will accelerate development and increase patient access to EB103."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-051361","json":"https://secwatch.observer/filing/0001213900-25-051361.json","markdown":"https://secwatch.observer/filing/0001213900-25-051361.md","text":"https://secwatch.observer/filing/0001213900-25-051361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025051361/0001213900-25-051361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025051361/ea0244733-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:41:45.117858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}